NGEN

+ Watchlist + Portfolio

NervGen Pharma Corp.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.76
52-Week Range: $1.58 – $6.30
Market Cap: $191.39M
P/E (TTM): —
EPS (TTM): -0.57
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 15.37
PEG Ratio: —
Return on Equity: -757.48%
Return on Assets: -37.70%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 1.23
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $38.39M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $104.60M

NGEN Income statement, annual periods, in CAD
CAD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$16.61M	$8.05M	$15.81M	$13.91M
Selling, General & Admin	$6.34M	$9.63M	$9.34M	$11.17M
Operating Expenses	$23.03M	$17.78M	$25.18M	$25.08M
Operating Income	-$23.03M	-$17.78M	-$25.18M	-$25.08M
EBITDA	-$20.09M	-$17.63M	-$25.09M	-$25.02M
Pretax Income	-$20.72M	-$22.38M	-$24.25M	-$44.12M
Net Income	-$20.72M	-$22.38M	-$24.25M	-$44.12M
Diluted EPS	-0.39	-0.38	-0.36	-0.61
Diluted Shares	52.65M	59.29M	67.32M	72.33M

NGEN Balance Sheet statement, annual periods, in CAD
CAD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$22.45M	$11.66M	$17.27M	$22.07M
Receivables	$27.03K	$250.21K	$415.30K	$80.83K
Current Assets	$23.15M	$12.52M	$19.01M	$22.80M
Total Assets	$23.88M	$13.24M	$19.49M	$23.21M
Current Liabilities	$10.22M	$15.14M	$16.90M	$19.73M
Total Debt	$283.45K	$197.19K	$105.60K	$8.37K
Total Liabilities	$10.41M	$15.25M	$16.91M	$19.73M
Retained Earnings	-$55.77M	-$78.15M	-$102.65M	-$146.76M
Shareholders' Equity	$13.46M	-$2.01M	$2.58M	$3.48M
Working Capital	$12.93M	-$2.62M	$2.11M	$3.07M

NGEN Cash Flow statement, annual periods, in CAD
CAD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$17.78M	-$11.30M	-$16.84M	-$19.50M
Capital Expenditure	-$21.11K	-$141.40K	—	—
Free Cash Flow	-$17.81M	-$11.44M	-$16.84M	-$19.50M
Depreciation & Amortisation	$115.11K	$145.00K	$83.80K	$55.80K
Stock-Based Compensation	$2.77M	$6.04M	$6.04M	$5.39M
Investing Cash Flow	-$21.11K	-$138.85K	$58.87K	$100.93K
Financing Cash Flow	$22.64M	$766.28K	$22.70M	$23.76M
Net Change in Cash	$4.84M	-$10.67M	$5.91M	$4.37M

NGEN Income statement, quarterly periods, in CAD
CAD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$3.15M	$2.71M	$4.44M	$3.60M	$4.86M	$7.89M
Selling, General & Admin	$2.89M	$3.76M	$1.73M	$2.80M	$2.67M	$4.31M
Operating Expenses	$6.04M	$6.47M	$6.17M	$6.40M	$7.53M	$12.20M
Operating Income	-$6.04M	-$6.47M	-$6.17M	-$6.40M	-$7.53M	-$12.20M
EBITDA	-$6.02M	-$6.46M	-$6.16M	-$6.39M	-$7.52M	-$12.18M
Pretax Income	-$3.95M	-$9.10M	-$4.16M	-$26.91M	-$1.68M	-$29.22M
Net Income	-$3.95M	-$9.10M	-$4.16M	-$26.91M	-$1.68M	-$29.22M
Diluted EPS	-0.06	-0.13	-0.06	—	-0.09	-0.32
Diluted Shares	70.67M	71.96M	73.16M	—	80.86M	92.44M

NGEN Balance Sheet statement, quarterly periods, in CAD
CAD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$17.27M	$15.67M	$11.36M	$22.07M	$16.56M	$86.79M
Receivables	$415.30K	$96.95K	$344.20K	$80.83K	$93.53K	$200.24K
Current Assets	$19.01M	$16.49M	$12.65M	$22.80M	$20.37M	$89.81M
Total Assets	$19.49M	$16.92M	$13.08M	$23.21M	$20.77M	$90.19M
Current Liabilities	$16.90M	$17.84M	$16.02M	$19.73M	$15.22M	$72.91M
Total Debt	$105.60K	$57.71K	$33.23K	$8.37K	$0.00	$0.00
Total Liabilities	$16.91M	$17.84M	$16.02M	$19.73M	$15.22M	$72.91M
Retained Earnings	-$102.65M	-$115.21M	-$119.85M	-$146.76M	-$148.44M	-$177.66M
Shareholders' Equity	$2.58M	-$918.42K	-$2.94M	$3.48M	$5.54M	$17.28M
Working Capital	$2.11M	-$1.36M	-$3.36M	$3.07M	$5.15M	$16.90M

NGEN Cash Flow statement, quarterly periods, in CAD
CAD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$3.66M	-$3.67M	-$5.32M	-$6.40M	-$8.20M	-$5.73M
Free Cash Flow	-$3.66M	-$3.67M	-$5.32M	-$6.40M	-$8.20M	-$5.73M
Depreciation & Amortisation	$15.81K	$13.95K	$13.95K	$13.95K	$13.95K	$13.95K
Stock-Based Compensation	$1.67M	$2.02M	$1.11M	$802.53K	$952.13K	$2.74M
Investing Cash Flow	$25.23K	$25.23K	$25.23K	$25.23K	$8.41K	$0.00
Financing Cash Flow	$310.00K	$4.75M	$995.20K	$16.74M	$2.78M	$78.15M
Net Change in Cash	-$3.32M	$1.11M	-$4.30M	$10.37M	-$5.41M	$72.41M

Market Snapshot

About

NervGen Pharma is a clinical-stage biotech company developing treatments for nerve damage and spinal cord injuries. The company focuses on therapies that promote nerve regeneration and repair using its proprietary platform, targeting conditions including traumatic spinal cord injury, multiple sclerosis, and peripheral nerve damage.